INVESTIGATION OF CROSS IMMUNITY FOLLOWING VACCINATION WITH ALLOGENIC CANCER CELL

同种异体癌细胞疫苗接种后交叉免疫的研究

• 批准号: 7376297
• 负责人: PAUL O SCHWARZENBERGER
• 金额: $ 1.98万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376297
• 关键词: INVESTIGATION; CROSS; IMMUNITY; FOLLOWING; VACCINATION

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. We are currently conducting a lung cancer clinical vaccine trial which is using gene modified cancer cells. The design of this ongoing vaccine study is geared to investigate whether immunity specifically directed against the allogenic cell lines used as the actual vaccine will develop. Appropriate assays will be performed which includes cytotoxic T-lymphocyte assays, as well as cytokine assays and clinical evaluation for tumor responses. Participating subjects already have provided appropriate consents. In order to perform additional important immunological assays from archived blood, we propose and investigator initiated component. We propose to examine whether a response against other lung cell lines has developed. This response would be specifically against cell lines the subjects had not been vaccinated during the vaccination process. These studies will be performed on lymphocytes and serum obtained from naive subjects (prior to vaccination) and subjects following each of the four vaccinations. These tissues and serum are archived and cryopreserved and propsed studies will be conducted in vitro.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。我们目前正在进行使用基因改良癌细胞的肺癌临床疫苗试验。这项正在进行的疫苗研究的设计旨在调查是否针对用作实际疫苗的同种异体细胞系专门针对的免疫力。将进行适当的测定法，其中包括细胞毒性T淋巴细胞测定，以及细胞因子测定和肿瘤反应的临床评估。参与主题已经提供了适当的同意。为了从存档的血液中进行其他重要的免疫学测定，我们提出和研究者启动组件。我们建议检查是否已经对其他肺细胞系的反应产生。这种反应将针对细胞系特别是对受试者在疫苗接种过程中未接种疫苗的反应。这些研究将对从幼稚受试者（疫苗接种之前）获得的淋巴细胞和血清进行，以及四个疫苗接种中的每个受试者。这些组织和血清是存档和冷冻保存的，并且将在体外进行支撑研究。